The United Kingdom and the United States have hammered out a key bilateral deal that will keep zero tariffs on UK drug exports going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to boost funding on drugs through the NHS. This pledge ensures that import taxes on these crucial exports will stay at zero for a duration of the next three years.
This deal follows recent warnings to hike tariffs on branded pharmaceutical products, with figures mentioned up to one hundred percent.
"This deal with the Britain strengthens the international landscape for innovative medicines and brings long-overdue equity to transatlantic pharmaceutical trade," a statement said.
Trade Impact
Pharmaceuticals represent one of the UK's largest export categories to the America, which is by far the primary buyer for large companies like GSK and AstraZeneca.
Trade data reveal that in the year leading up to the third quarter, the UK shipped pharmaceutical products valued at billions to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This deal safeguards employment, increases investment and sets the stage for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Key British Pledges
The deal entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to double total public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates exceeded twenty percent.
Recent Tensions
The deal comes amid a protracted dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
The disagreement were exacerbated by claims that US patients were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several large drug company projects in the UK have been halted or scrapped, while major funding commitments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS must invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.
